PMID- 38164418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240103
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - Application of Metabolomics and Traditional Chinese Medicine for Type 2 Diabetes 
      Mellitus Treatment.
PG  - 4269-4282
LID - 10.2147/DMSO.S441399 [doi]
AB  - Diabetes is a major global public health problem with high incidence and case 
      fatality rates. Traditional Chinese medicine (TCM) is used to help manage Type 2 
      Diabetes Mellitus (T2DM) and has steadily gained international acceptance. 
      Despite being generally accepted in daily practice, the TCM methods and 
      hypotheses for understanding diseases lack applicability in the current 
      scientific characterization systems. To date, there is no systematic evaluation 
      system for TCM in preventing and treating T2DM. Metabonomics is a powerful tool 
      to predict the level of metabolites in vivo, reveal the potential mechanism, and 
      diagnose the physiological state of patients in time to guide the follow-up 
      intervention of T2DM. Notably, metabolomics is also effective in promoting TCM 
      modernization and advancement in personalized medicine. This review provides 
      updated knowledge on applying metabolomics to TCM syndrome differentiation, 
      diagnosis, biomarker discovery, and treatment of T2DM by TCM. Its application in 
      diabetic complications is discussed. The combination of multi-omics and 
      microbiome to fully elucidate the use of TCM to treat T2DM is further envisioned.
CI  - (c) 2023 Li et al.
FAU - Li, Jing
AU  - Li J
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, 
      People's Republic of China.
FAU - Zhu, Na
AU  - Zhu N
AD  - Clinical Trial Research Center, Affiliated Qingdao Central Hospital of Qingdao 
      University, Qingdao Central Hospital, Qingdao, People's Republic of China.
FAU - Wang, Yaqiong
AU  - Wang Y
AD  - Clinical Trial Research Center, Affiliated Qingdao Central Hospital of Qingdao 
      University, Qingdao Central Hospital, Qingdao, People's Republic of China.
FAU - Bao, Yanlei
AU  - Bao Y
AD  - Department of Pharmacy, Liaoyuan People's Hospital, Liaoyuan, People's Republic 
      of China.
FAU - Xu, Feng
AU  - Xu F
AD  - Clinical Trial Research Center, Affiliated Qingdao Central Hospital of Qingdao 
      University, Qingdao Central Hospital, Qingdao, People's Republic of China.
FAU - Liu, Fengjuan
AU  - Liu F
AD  - Clinical Trial Research Center, Affiliated Qingdao Central Hospital of Qingdao 
      University, Qingdao Central Hospital, Qingdao, People's Republic of China.
FAU - Zhou, Xuefeng
AU  - Zhou X
AD  - Clinical Trial Research Center, Affiliated Qingdao Central Hospital of Qingdao 
      University, Qingdao Central Hospital, Qingdao, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231228
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10758184
OTO - NOTNLM
OT  - diabetic complications
OT  - diagnosis
OT  - metabolomics
OT  - traditional Chinese medicine
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/03 05:36
MHDA- 2024/01/03 05:37
PMCR- 2023/12/28
CRDT- 2024/01/02 03:43
PHST- 2023/09/21 00:00 [received]
PHST- 2023/11/21 00:00 [accepted]
PHST- 2024/01/03 05:37 [medline]
PHST- 2024/01/03 05:36 [pubmed]
PHST- 2024/01/02 03:43 [entrez]
PHST- 2023/12/28 00:00 [pmc-release]
AID - 441399 [pii]
AID - 10.2147/DMSO.S441399 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 Dec 28;16:4269-4282. doi: 10.2147/DMSO.S441399. 
      eCollection 2023.